Related Experiment Video
Updated: Feb 20, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
41.6K
Indacaterol/glycopyrronium: a dual bronchodilator for COPD
Donald Banerji1, Robert Fogel1, Francesco Patalano2
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Drug Discovery Today
|October 29, 2017
Summary
Indacaterol/glycopyrronium (IND/GLY) is a once-daily treatment for chronic obstructive pulmonary disease (COPD). The IGNITE Phase 3 program confirmed its effectiveness in improving bronchodilation, symptom control, and reducing exacerbations.
Area of Science:
- Pulmonology
- Pharmacology
- Clinical Medicine
Background:
- Chronic obstructive pulmonary disease (COPD) requires improved treatment strategies for symptom control and exacerbation reduction.
- Indacaterol/glycopyrronium (IND/GLY) 110/50mcg is the first once-daily long-acting beta2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) approved in Europe.
- Current COPD management necessitates advancements in pharmacological interventions.
Purpose of the Study:
- To evaluate the efficacy of IND/GLY in optimizing bronchodilation in COPD patients.
- To assess the impact of IND/GLY on reducing symptoms and exacerbation frequency in COPD.
- To challenge existing paradigms in the pharmacological treatment of COPD.
Main Methods:
- The IGNITE program, an adaptive, comprehensive, and innovative Phase 3 development study, was employed.
- Efficacy endpoints focused on bronchodilation, symptom burden, and exacerbation rates.
- Patient populations were representative of those with moderate to severe COPD.
Main Results:
- IND/GLY demonstrated significant improvements in bronchodilation compared to placebo or other relevant comparators.
- Patients treated with IND/GLY experienced a notable reduction in symptom scores.
- A significant decrease in the frequency of COPD exacerbations was observed in the IND/GLY group.
Conclusions:
- IND/GLY 110/50mcg represents a significant advancement in COPD pharmacotherapy.
- The IGNITE program provides robust evidence for the efficacy of this LABA/LAMA FDC.
- IND/GLY offers an effective option for optimizing COPD management through improved symptom control and reduced exacerbations.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
874
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
874
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.8K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.8K
01:23Inhaled Medications
868
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
868
01:28Adrenergic Agonists: Mixed-Action Agents
1.6K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.6K
01:24Antiasthma Drugs: Methylxanthines
1.8K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.8K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.3K